Celltrion USA, Inc

Reimagining pharmaceutical innovation, this company is at the forefront of healthcare evolution, dedicated to transforming patient access to life-altering therapies. Based in the strategic locale of Jersey City, it leverages advanced biotechnology to deliver a robust lineup of FDA-approved biosimilars and biologics that reshape treatment standards in the U.S.

Specializing in high-quality biosimilars, their portfolio includes critical therapies like INFLECTRA®, TRUXIMA®, and HERZUMA®. Noteworthy among their innovations is ZYMFENTRA®, acclaimed as the first subcutaneous infliximab available in the U.S., offering enhanced patient convenience and optimized therapeutic outcomes.

With a commitment to expanding therapeutic horizons, this enterprise boasts a promising pipeline of biosimilars, including candidates like CT-P41 and CT-P47. Their dedication extends to regulatory milestones, with OMLYCLO® distinguished as the sole interchangeable biosimilar with XOLAIR®.

Powered by a customer-centric philosophy and driven by a visionary approach, the company is a beacon of advancement in the pharmaceutical landscape. It consistently prioritizes broadening patient access to innovative treatments, underpinned by a strong heritage and strategic global partnerships.

Expertise in high-standard biologics and biosimilars
Innovative product offerings tailored for patient convenience
Strategic U.S. positioning in Jersey City for nationwide impact
Commitment to regulatory achievements and therapy access